12:00 AM
 | 
Mar 05, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Glivec regulatory update

The European Commission approved an expanded label for Glivec imatinib from Novartis to include the treatment of adult patients following surgical removal of stem cell factor ( SCF) receptor tyrosine kinase (c-Kit; KIT; ...

Read the full 165 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >